

## VBC Release Highlights

March 24, 2023

Practice Insights<sup>SM</sup> is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

### MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect the below refinement(s) for:

Measure	Update	Practice Impact
MIPS 047: Advance Care Plan	A refinement has been made to remove the following Denominator Qualifying CPT codes based on the 2023 measure specification updates: 99218, 99219, 99220, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337.	Practices might see a shift in the denominator.
MIPS 110: Preventive Care and Screening: Influenza Immunization	For 2023, this measure has been removed from the MIPS Quality Measure Dashboard.	
PIMSH 12: Covid-19 Vaccinations	For 2023, this measure has been removed from the MIPS Quality Measure Dashboard.	

### Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will

---

continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

**NOTE:** Table continues on the next page.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#047	Advance Care Plan
#104	Combination Androgen Deprivation Therapy for Prostate
#134	Depression Screening
#143	Pain Intensity Quantified
#144	Pain Care Plan
#450	Trastuzumab Received by Patients with AJCC Stage (T1c), II, and III and HER2+ Breast Cancer Receiving Adj Chemo
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting

Measure	Description
	Drugs